AstraZeneca says EU regulator recommends Enhertu approval for early breast cancer
AstraZeneca Plc said the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended Enhertu for approval as adjuvant treatment for HER2-positive early breast cancer.
Sept. 21 — AstraZeneca PLC said the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended Enhertu for approval in the EU as an adjuvant treatment for HER2-positive early breast cancer.